Labrie Laboratory

Selected Publications

Marshall LL, Killinger BA, Ensink E, Li P, Li KX, Cui W, Lubben N, Weiland M, Wang X, Gordevicius J, Coetzee GA, Ma J, Jovinge S, Labrie V. 2020. Epigenomic analysis of Parkinson’s disease neurons identifies Tet2 loss as neuroprotective. Nat Neuro.

Li P, Ensink E, Lang S, Marshall L, Schilthuis M, Lamp J, Vega I, Labrie V. 2020. Hemispheric asymmetry in the human brain and in Parkinson’s disease is linked to divergent epigenetic patterns in neurons. Genome Biol 21:61.

Li P, Marshall L, Oh G, Jakubowski JL, Groot D, He Y, Wang T, Petronis A, Labrie V. 2019. Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive decline. Nat Comm.

Pai S, Li P, Killinger B, Marshall L, Jia P, Liao J, Petronis A, Szabó P, Labrie V. 2019. Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. Nat Comm.

Chen X, Kordich JK, Williams ET, Levine N, Cole-Strauss A, Marshall L, Labrie V, Ma J, Lipton JW, Moore DJ. 2019. Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A.

Oh G, Koncevicius K, Ebrahimi S, Carlucci M, Groot DE, Nair A, Zhang A, Krisciunas A, Oh ES, Labrie V, Wong AHC, Gordeviscius J, Jia P, Susic M, Petronis A. 2019. Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging and complex disease. Genome Biol 20(1):2.

Labrie V, Brundin L. 2018. Harbingers of mental illness—infections associated with an increased risk for neuropsychiatric illness in children. JAMA Psych.

Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. 2018. Triggers, facilitators and aggravators: Redefining Parkinson’s disease pathogenesis. Trends Neurosci.

Killinger BA*, Madaj Z*, Sikora JW, Rey N, Haas AJ, Vepa Y, Lindqvist D, Chen H, Thomas PM, Brundin P, Brundin L, Labrie V. 2018. The veriform appendix impacts the risk of developing Parkinson’s. Sci Transl Med 10(465):eaar5280.

Thirtamara-Rajamani K, Li P, Escobar Galvis ML, Labrie V, Brundin P, Brundin L. 2017. Is the enzyme ACMSD a novel therapeutic target in Parkinson’s disease?J Parkinson Dis 7(4):577–587.

Oh E, Jeremian R, Oh G, Groot D, Susic M, Lee K, Foy K, Laird PW, Petronis A, Labrie V. 2017. Transcriptional heterogeneity in the lactase gene within cell-type is linked to the epigenome. Sci Rep 7:41843.

Labrie V, Buske OJ, Oh E, Jeremian R, Ptak C, Gasiunas G, Maleckas A, Petereit R, Zvirbliene A, Adamonis K, Kriukiene E, Koncevicius K, Gordevicius J, Nair A, Zhang A, Ebrahimi S, Oh G, Siksnys V, Kupcinskas L, Brudno M, Petronis A. 2016. Lactase nonpersistence is directed by DNA-variation-dependent epigenetic aging. Nat Struct Mol Biol 23:566-573.

Kriukiene E*, Labrie V*, Khare T, Urbanaviciute G, Lapinaite A, Koncevicius K, Li D, Wang T, Pai S, Ptak C, Gordevicius J, Wang SC, Petronis A, Klimasauskas S. 2013. DNA unmethylome profiling by covalent capture of CpG sites. Nat Comm 4:2190.
*Joint first author

Khare T, Pai S, Koncevicius K, Pal M, Kriukiene E, Liutkeviciute Z, Irimia M, Jia P, Ptak C, Xia M, Tice R, Moréra S, Nazarians A, Belsham D, Wong AHC, Blencowe BJ, Wang SC, Kapranov P, Kustra R, Labrie V, Klimasauskas S, Petronis A. 2012. 5-hmC in the brain: abundance in synaptic genes and differences at the exon-intron boundary. Nat Struc Mol Biol 19(10):1037–1043.

Labrie V, Pai S, Petronis A. 2012. Epigenetics of major psychosis: progress, problems and perspectives. Trends Genet 28(9):427–435.

Labrie V, Wong AHC, Roder JC. 2012. Contributions of the D-serine pathway to schizophrenia. Neuropharmacology. 62(3):1484–1503.

Thompson M, Marecki JC, Marinesco S, Labrie V, Roder JC, Barger SW, Crow JP. 2012. Paradoxical roles of serine racemase and D-serine in the G93A mSOD1 mouse model of ALS. J Neurochem 120(4):598–610.

Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A, Dong A, Tempel W, Wang SC, Chen X, Chau I, Mangano TJ, Huang XP, Simpson CD, Pattenden SG, Norris JL, Kireev DB, Tripathy A, Edwards A, Roth BL, Janzen WP, Garcia BA, Petronis A, Ellis J, Brown PJ, Frye SV, Arrowsmith CH, Jin J. 2011. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 7(8):566–574.

Labrie V. Histone deacetylase inhibitors: a novel therapeutic approach for cognitive disorders. In: Petronis A & Mill J (Eds.), Brain, Behavior and Epigenetics. Berlin: Springer; 2010. p.291–308.

Labrie V, Roder JC. The role of the NMDA receptor glycine site in the etiology and pharmacotherapy of anxiety syndromes. In: Sher L & Vilens A (Eds.), Neurobiology of Post-traumatic Stress Disorder New York (NY): Nova Science Publishers, Inc; 2010. p.291–308.

Labrie V, Roder JC. 2010. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev 34(3):351–372.

Labrie V, Wei W, Barger S, Baker GB, Roder JC. 2010. Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice. Genes Brain Behav 9(1):11–25.

Rauw GR, Grant SL, Labrie V, Roder J, Antflick J, Hampson D, Baker GB. 2010. Determination of L-serine-Ophosphate in rat and mouse brain tissue using high-performance liquid chromatography and fluorimetric detection. Anal Biochem 405(2):260–262.

Sarras H, Semeralul MO, Fadel MP, Feldcamp LA, Labrie V, Wong AH. 2010. Elevated PICK1 mRNA in schizophrenia increased SRR mRNA in suicide. Schizophr Res 120(1-3):236–237.

Labrie V, Fukumura R, Rastogi A, Fick LJ, Wang W, Boutros PC, Kennedy JL, Semeralul MO, Lee FH, Baker GB, Belsham DD, Barger SW, Gondo Y, Wong AH, Roder JC. 2009. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet 18(17):3227–3243.

Labrie V, Clapcote SJ, Roder JC. 2009. Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors. Pharmacol Biochem Behav 91(4):610–620.

Labrie V, Duffy S, Wei W, Barger S, Baker GB, Roder JC. 2008. Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice. Learn Mem 16(1):28–37.
*Journal cover image and editor’s pick

Labrie V, Lipina T, Roder JC. 2008. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 200(2):217–230.

Duffy S*, Labrie V*, Roder JC. 2008. D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. Neuropsychopharmacology 33(5): 1004–1018.
*Joint first author

Lipina T, Labrie V, Weiner I, Roder JC. 2005. Modulators of the glycine site on NMDA receptors, D-serine and ALX-5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179(1):54–67.